Clinical Trials Logo

Filter by:
NCT ID: NCT05558670 Recruiting - Clinical trials for Disorders of Consciousness

Brain Network Characteristics in Patients With Disorders of Consciousness

Start date: September 2022
Phase:
Study type: Observational

Simultaneous measurement of the three modalities, functional magnetic resonance imaging (fMRI), positron emission tomography (PET) and electroencephalography (EEG) was proven to be feasible and advantageous in evaluating brain structural and functional (via fMRI), metabolic (via PET) and electrophysiological (via EEG) signatures simultaneously under the same conditions. Investigators use trimodal PET-fMRI-EEG imaging to explore the characteristics of brain network damage in patients with disorders of consciousness(DOC), assess the trajectory of consciousness recovery in a prospective observational cohort study.

NCT ID: NCT05558111 Recruiting - Clinical trials for Orthotopic Neobladder

The Supraspinal Control of Lower Urinary Tract Function in Patients With Orthotopic Sigmoid Neobladder.

Start date: June 1, 2022
Phase:
Study type: Observational

Orthotopic sigmoid neobladder surgery is one of the ideal urinary diversion methods after radical cystectomy.In recent years, functional imaging studies have revealed brain regions related to urinary system function, but brain activity of lower urinary tract function in neobladder patients is still unclear.The aim of this study is to explore the brain activity of urination intention and self-controlled urination behavior in patients with orthotopic sigmoid neobladder by task-state functional magnetic resonance imaging (fMRI).

NCT ID: NCT05557903 Recruiting - Clinical trials for Lymphoma, Non-Hodgkin

Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL

Start date: December 20, 2021
Phase: Phase 1
Study type: Interventional

Phase I clinical study of multicenter, single-arm, open, non-randomized evaluation of recombinant humanized anti-CD52 monoclonal antibody in the NHL and T-PLL

NCT ID: NCT05557838 Recruiting - Clinical trials for Hepatocellular Carcinoma

Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma

TREMENDOUS
Start date: February 22, 2023
Phase: Phase 3
Study type: Interventional

This is a prospective, open label, multi-center, interventional study to assess the safety and efficacy of Druvalumab plus Tremelimumab as first-line treatment in Chinese patients with unresectable hepatocellular carcinoma.

NCT ID: NCT05557786 Recruiting - Clinical trials for Spinocerebellar Ataxia Type 3

Treatment of Transcranial Alternating Current Stimulation(tACS)on Cerebellar Ataxia

Start date: August 1, 2022
Phase:
Study type: Observational

This is a longitudinal, triple-blind, randomized-controlled, prospective observational study assessing patients with cerebellar ataxia, including spinocerebellar ataxia type 3 (SCA3) and multiple system atrophy-cerebellar type (MSA-C), to examine the efficacy, safety, and tolerability of transcranial alternating current stimulation (tACS) for up to 3 months.

NCT ID: NCT05557578 Recruiting - Clinical trials for Intrahepatic Cholangiocarcinoma

GOT Applied as Neoadjuvant Regimen for Patients of Resectable ICC With High-risk Factors of Recurrence

GOT
Start date: May 5, 2023
Phase: Phase 2
Study type: Interventional

Intrahepatic cholangiocarcinoma (ICC) arises from the epithelial cells of bile ducts and occurs proximal to the segmental biliary ducts. ICC is highly aggressive, long-term survival only can be achieved in patients with R0 surgical resection. Large diameter of tumor, multiple tumors, preoperative carbohydrate antigen(CA)19-9 elevated, tumors invaded adjacent blood vessels and preoperative radiology hints suspected regional lymph node metastasis were considered as high-risk factors of recurrence in the previous study. Chemotherapy can trigger antigen release and induces strong anti-tumor effects of T cells due to cytotoxic cell death. Immune checkpoint inhibitors can relieve tumor immunosuppressive microenvironment. Hence, we aim to investigate objective response rate and R0 resection rate and survival rate of patients with high-risk factors of recurrence who receives Tislelizumab combined with GEMOX regimen(GOT) as a neoadjuvant therapy.

NCT ID: NCT05557565 Recruiting - Cervical Cancer Clinical Trials

A Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Cervical Cancer

Start date: December 21, 2021
Phase: Phase 2
Study type: Interventional

This is a single-arm, open-label, multicenter, phase II trial to evaluate the efficacy and safety of QL1706 in patients with recurrent or metastatic cervical cancer.

NCT ID: NCT05557552 Recruiting - Clinical trials for Non-small Cell Lung Cancer Stage III

Sequential Chemo-immunotherapy Plus Thoracic Radiotherapy for Elderly and/or Frail Stage III Non-small-cell Lung Cancer

Start date: September 30, 2022
Phase: N/A
Study type: Interventional

Concurrent chemoradiotherapy without disease progression followed by consolidation durvalumab is standard of care for unresectable, stage III non-small-cell lung cancer (NSCLC) (the 'PACIFIC regimen'). However, many patients with poor performance status, older age or comorbidities may be ineligible for chemotherapy due to expected high toxicity. The present study aim to investigate the efficacy and toxicities of sequential chemo-immunotherapy plus thoracic radiotherapy for elderly and/or frail stage III NSCLC patients unfit for concurrent chemoradiotherapy, and to identify the optimal thoracic dose for this patient population.

NCT ID: NCT05557357 Recruiting - Tinnitus Clinical Trials

Electroacupuncture With or Without Combined Warm Needling for Tinnitus

Start date: December 1, 2022
Phase: N/A
Study type: Interventional

This randomized controlled trial aims to evaluate the efficacy and safety of either electroacupuncture alone or combined with warm needling in reducing tinnitus loudness and improving the impairment caused by tinnitus in Hong Kong.

NCT ID: NCT05557240 Recruiting - Glioma, Malignant Clinical Trials

Neoantigens Phase I Trial in Newly Diagnosed Glioblastoma Patients

Start date: September 13, 2022
Phase: N/A
Study type: Interventional

The primary objective of this study is to assess the safety and tolerability, feasibility of the NeoPep Vaccine in newly diagnosed glioblastoma (GB) patients.